Antiviral Activity of AZD7295 in HCV Carriers

Arrow Therapeutics

Status and phase: Completed; Phase 1

Conditions: Hepatitis C

Treatments: Drug: AZD7295; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00781976

HCV689-102

Details and patient eligibility

About

PK, safety study of AZD7295 in HCV carriers

Enrollment: 31 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCV carrier

Exclusion criteria

• concurrent medications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

31 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: Placebo

2

Active Comparator group

Treatment:

Drug: AZD7295